Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Xenetic Biosciences (3XB0) Stock Price & Analysis

0 Followers

3XB0 Stock Chart & Stats

€3.86€0.00(0.00%)
At close: 5:30 PM GMT+1
€4€6€8Sep 19Jan 31Mar 7Oct 1
Day’s Range
EUR 3.86 - EUR 4.00
52-Week Range
EUR 3.86 - EUR 4.00
Previous Close
EUR 3.86
Volume
N/A
Average Volume (3M)
0
Market Cap
EUR 3.78M
Enterprise Value
EUR 204.83K
Total Cash (Recent Filing)
EUR 6.47M
Total Debt (Recent Filing)
EUR 0
Price to Earnings (P/E)
―
Beta
N/A
Next Earnings
May 13, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue Growth

TTM revenue growth of about 2.22 and continued expansion across prior annual periods indicate increasing commercial activity. If sustained, this top-line momentum can improve operating leverage and support development investment, although profitability is not yet established.

Gross Margin

Reported gross margins of about 80% TTM and 100% in prior annual reports indicate a favorable cost structure on current revenue. Maintaining that profile would give future revenue a strong contribution margin and create a path toward better operating leverage as programs scale.

Pipeline Expansion

The proposed Santersus acquisition would broaden Xenetic's clinical pipeline across sepsis, lupus, transplantation and oncology. FDA Breakthrough Device-designated pivotal-stage assets could provide multiple development catalysts and diversify the company's therapeutic opportunity set.

Bears Say

Persistent Losses

TTM net margin of roughly -76%, with EBIT and EBITDA meaningfully negative, shows revenue has not yet scaled enough to cover operating costs. Persistent operating losses constrain internally funded R&D and leave future earnings dependent on successful development and commercialization.

Cash Burn

Operating and free cash flow are negative in every period shown, including about -$2.3M TTM. Although burn improved from prior years, continued cash consumption means the company cannot yet fund operations internally and remains reliant on external funding.

Transaction Dilution

The all-stock Santersus transaction would transfer roughly 85% fully diluted ownership to Santersus investors and shift control toward its designees. Required approvals, exchange-ratio changes and Nasdaq compliance create durable execution and post-transaction financing risks.

Xenetic Biosciences News

3XB0 FAQ

What was Xenetic Biosciences’s price range in the past 12 months?
Xenetic Biosciences lowest stock price was €3.86 and its highest was €4.00 in the past 12 months.
What is Xenetic Biosciences’s market cap?
Xenetic Biosciences’s market cap is €3.78M.
When is Xenetic Biosciences’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Xenetic Biosciences’s earnings last quarter?
Xenetic Biosciences released its earnings results on Aug 07, 2026. The company reported -€0.367 earnings per share for the quarter.
Is Xenetic Biosciences overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Xenetic Biosciences pay dividends?
Xenetic Biosciences does not currently pay dividends.
What is Xenetic Biosciences’s EPS estimate?
Xenetic Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Xenetic Biosciences have?
Xenetic Biosciences has 2,343,181 shares outstanding.
What happened to Xenetic Biosciences’s price movement after its last earnings report?
Xenetic Biosciences reported an EPS of -€0.367 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Xenetic Biosciences?
Currently, no hedge funds are holding shares in DE:3XB0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology